Who is sponsoring NCT04115930?

NCT04115930 is sponsored by University of Eastern Finland.

What drugs are being tested in NCT04115930?

Interventions in NCT04115930: Physical Activity measurement:.

What condition does NCT04115930 study?

NCT04115930 studies Relapsing Remitting Multiple Sclerosis, Fatigue, Quality of Life, Physical Activity.

Is NCT04115930 still recruiting?

NCT04115930 is currently completed. Last updated 4 October 2019.

Last reviewed 2019-10-04 · How we verify

NCT04115930: PAMS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients

Completed Last updated 4 October 2019

What this trial tests

trial testing Physical Activity measurement: in Relapsing Remitting Multiple Sclerosis in 61 participants. Completed in 13 June 2019.

Timeline

16 May 2018

Primary endpoint
13 June 2019

13 June 2019

Quick facts

Lead sponsor	University of Eastern Finland
Status	Completed
Study type	OBSERVATIONAL
Enrollment	61
Start date	16 May 2018
Primary completion	13 June 2019
Estimated completion	13 June 2019
Sites	4 locations across Finland

Drugs / interventions tested

Physical Activity measurement:

Conditions studied

Relapsing Remitting Multiple Sclerosis — all drugs for Relapsing Remitting Multiple Sclerosis →
Fatigue — all drugs for Fatigue →
Quality of Life — all drugs for Quality of Life →
Physical Activity — all drugs for Physical Activity →

Sponsor

University of Eastern Finland

Who can join

Adults 18 to 55, any sex, with Relapsing Remitting Multiple Sclerosis or Fatigue. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of the study is to assess the fatigue, cognition, quality of life and disability correlation to MS-patients daily physical activity.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Correlation of Cognition With Disability and Physical Performance in Patients With Relapsing-Remitting MS.
Luostarinen M, Portaankorva AM, Urpilainen P, Takala S, et al · · 2025 · PMID 40535778 · DOI 10.1177/11795735251349716

Verify or expand the search:

Other recruiting trials for Relapsing Remitting Multiple Sclerosis

Currently open trials in the same condition.

NCT06796504 — The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study · NA · recruiting
NCT05949580 — Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple · recruiting
NCT06282081 — Serum Neurofilament Light in Multiple Sclerosis · active not recruiting
NCT05327322 — Functional Outcomes From Diets in Multiple Sclerosis · NA · active not recruiting
NCT05171972 — Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment · active not recruiting

Other University of Eastern Finland trials

Trials by the same sponsor.

NCT07369570 — Evolution of Lesions in Repeated Biparametric Prostate Magnetic Resonance Imaging · NA · recruiting
NCT07430007 — Exercise and Dietary Lifestyle Intervention on Reducing Atrial Fibrillation Burden, Cardiac and Body Fat Mass. · NA · recruiting
NCT06923735 — Nutrition Apps in Occupational Healthcare (Pilot Study of the FOODNUTRI Project) · NA · enrolling by invitation
NCT06495801 — Effectiveness of a Mobile Application in Improving Employees' Social Well-being. · NA · active not recruiting
NCT06438276 — Psychiatric Outreach Nurses Supporting Adolescent Mental Health · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04115930 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Eastern Finland
Last refreshed: 4 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04115930.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing